RxDoctor Payments Data

Nouneh Danielyan, MD

Geriatric Medicine · Los Angeles, CANPI 1871520726

Payments from drug & device makers

$444in general payments, 2019–2025

Across 20 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akorn Operating Company LLC$166
  • CSL Behring$100
  • Amgen$80
  • AbbVie$60
  • Johnson & Johnson$38

What the payments were for

  • Food & beverage$444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Akorn Operating Company LLC9$166
CSL Behring1$100
Amgen5$80
AbbVie3$60
Johnson & Johnson2$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$444 in reported general payments places this provider in the 65th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$246,984
Medicare patients
508
Services billed
3,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl931$538,402
VascepaIcosapent Ethyl1,671$416,387
FarxigaDapagliflozin Propanediol610$354,256
JardianceEmpagliflozin431$255,095
OzempicSemaglutide185$172,244
LinzessLinaclotide246$130,222
Repatha SureclickEvolocumab225$125,835
CreonLipase/Protease/Amylase72$71,929
EliquisApixaban113$69,135
JanuviaSitagliptin Phosphate108$66,484
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog215$60,460
MounjaroTirzepatide55$56,362
Icosapent Ethyl485$55,335
MyrbetriqMirabegron107$47,458
Dexlansoprazole DrDexlansoprazole249$40,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$60$202,151318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →